Search

Your search keyword '"Ceccaldi, Pierre-François"' showing total 150 results
Start Over Author "Ceccaldi, Pierre-François" Language english
150 results on '"Ceccaldi, Pierre-François"'

6. Willingness to use clinical scales for menopause management among general practitioners.

Author

Farah, Diana, Ceccaldi, Pierre-François, Farah, Line, Ayoubi, Jean-Marc, and Vallée, Alexandre

Subjects
*MEDICAL care, *EVIDENCE gaps, *GENERAL practitioners, *DIGITAL health, *CLIMACTERIC
Abstract

AbstractObjectivesMethodResultsConclusionThe use of digital healthcare technologies to enhance healthcare delivery has seen significant growth. However, a notable a notable research gap exists in the application of clinical scales for menopause management by general practitioners (GPs). This study aims to investigate willingness of GPs to use specific menopausal scale tools in the care of females for menopause management.An anonymous online survey was developed, which received responses from 348 French GPs in 2023. Multiple backward logistic regression was performed to identify the factors influencing the willingness to use a practical menopause management scale.In total, 87.93% of GPs are not familiar with the Greene Climacteric Scale and 90.52% are not familiar with the Menopause Quick 6 scale. In contrast, 90.52% would be interested in having access to such scales. The willingness to use a menopause management scale is associated with caring for menopausal females (odds ratio [OR] = 6.13, 95% confidence interval [CI] [2.08–18.08], p = 0.001), less experience (OR = 7.10, 95% CI [2.05–25.22], p = 0.002), the importance of health prevention in daily practice (comparing ‘very important’ to ‘not’, OR = 12.98, 95% CI [1.68–97.60], p = 0.004) and the use of a digital scale in daily practice for menopausal management (OR = 2.13, 95% CI [1.04–5.83], p = 0.014).Future research is essential in representative population to confirm these findings in menopause management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Moderate or intensive management of the active phase of second-stage labor and risk of urinary and anal incontinence: results of the PASST randomized controlled trial

Author

Dupuis, Ninon, Pizzoferrato, Anne-Cécile, Garabedian, Charles, Rozenberg, Patrick, Kayem, Gilles, Harvey, Thierry, Mandelbrot, Laurent, Doret, Muriel, Fuchs, Florent, Azria, Elie, Sénat, Marie-Victoire, Ceccaldi, Pierre-François, Seco, Aurélien, Chantry, Anne, and Le Ray, Camille

Published
2023
Full Text
View/download PDF

11. A snapshot of the Covid-19 pandemic among pregnant women in France

Author

Kayem, Gilles, Lecarpentier, Edouard, Deruelle, Philippe, Bretelle, Florence, Azria, Elie, Blanc, Julie, Bohec, Caroline, Bornes, Marie, Ceccaldi, Pierre-François, Chalet, Yasmine, Chauleur, Céline, Cordier, Anne-Gael, Desbrière, Raoul, Doret, Muriel, Dreyfus, Michel, Driessen, Marine, Fermaut, Marion, Gallot, Denis, Garabédian, Charles, Huissoud, Cyril, Luton, Dominique, Morel, Olivier, Perrotin, Franck, Picone, Olivier, Rozenberg, Patrick, Sentilhes, Loïc, Sroussi, Jeremy, Vayssière, Christophe, Verspyck, Eric, Vivanti, Alexandre J., Winer, Norbert, Alessandrini, Vivien, and Schmitz, Thomas

Published
2020
Full Text
View/download PDF

15. Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome

Author

Andrade, Filipe, Shukla, Akash, Bureau, Christophe, Senzolo, Marco, D'Alteroche, Louis, Heurgué, Alexandra, Garcia-Pagan, Juan-Carlos, Turon, Fanny, Oberti, Frédéric, Tripathi, Dhiraj, Roux, Olivier, Ceccaldi, Pierre-François, de Raucourt, Emmanuelle, Payancé, Audrey, Valla, Dominique, Plessier, Aurélie, and Rautou, Pierre-Emmanuel

Published
2018
Full Text
View/download PDF

16. Pollution and endometriosis: A deep dive into the environmental impacts on women's health.

Author

Vallée, Alexandre, Ceccaldi, Pierre‐François, Carbonnel, Marie, Feki, Anis, and Ayoubi, Jean‐Marc

Subjects
*ENDOMETRIOSIS, *WOMEN'S health, *POLLUTION, *WATER pollution, *WASTE management
Abstract

Background: The interaction between pollution and endometriosis is a pressing issue that demands immediate attention. The impact of pollution, particularly air and water pollution, or occupational hazards, on hormonal disruption and the initiation of endometriosis remains a major issue. Objectives: This narrative review aims to delve into the intricate connection between pollution and endometriosis, shedding light on how environmental factors contribute to the onset and severity of this disease and, thus, the possible public health policy implications. Discussion: Endocrine‐disrupting chemicals (EDCs) in pollutants dysregulate the hormonal balance, contributing to the progression of this major gynaecological disorder. Air pollution, specifically PM2.5 and PAHs, has been associated with an increased risk of endometriosis by enhancing chronic inflammation, oxidative stress, and hormonal imbalances. Chemical contaminants in water and work exposures, including heavy metals, dioxins, and PCBs, disrupt the hormonal regulation and potentially contribute to endometriosis. Mitigating the environmental impact of pollution is required to safeguard women's reproductive health. This requires a comprehensive approach involving stringent environmental regulations, sustainable practices, responsible waste management, research and innovation, public awareness, and collaboration among stakeholders. Conclusion: Public health policies have a major role in addressing the interaction between pollution and endometriosis in a long‐term commitment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Alternative to intensive management of the active phase of the second stage of labor: a multicenter randomized trial (Phase Active du Second STade trial) among nulliparous women with an epidural

Author

Le Ray, Camille, Rozenberg, Patrick, Kayem, Gilles, Harvey, Thierry, Sibiude, Jeanne, Doret, Muriel, Parant, Olivier, Fuchs, Florent, Vardon, Delphine, Azria, Elie, Sénat, Marie-Victoire, Ceccaldi, Pierre-François, Seco, Aurélien, Garabedian, Charles, and Chantry, Anne Alice

Published
2022
Full Text
View/download PDF

26. Computerized cardiotocography analysis during labor – A state‐of‐the‐art review.

Author

Ben M'Barek, Imane, Jauvion, Grégoire, and Ceccaldi, Pierre‐François

Subjects
FETAL heart rate monitoring, FETAL heart rate, FETAL anoxia, UTERINE contraction, LABOR (Obstetrics), DIAGNOSTIC ultrasonic imaging personnel
Abstract

Cardiotocography is defined as the recording of fetal heart rate and uterine contractions and is widely used during labor as a screening tool to determine fetal wellbeing. The visual interpretation of the cardiotocography signals by the practitioners, following common guidelines, is subject to a high interobserver variability, and the efficiency of cardiotocography monitoring is still debated. Since the 1990s, researchers and practitioners work on designing reliable computer‐aided systems to assist practitioners in cardiotocography interpretation during labor. Several systems are integrated in the monitoring devices, mostly based on the guidelines, but they have not clearly demonstrated yet their usefulness. In the last decade, the availability of large clinical databases as well as the emergence of machine learning and deep learning methods in healthcare has led to a surge of studies applying those methods to cardiotocography signals analysis. The state‐of‐the‐art systems perform well to detect fetal hypoxia when evaluated on retrospective cohorts, but several challenges remain to be tackled before they can be used in clinical practice. First, the development and sharing of large, open and anonymized multicentric databases of perinatal and cardiotocography data during labor is required to build more accurate systems. Also, the systems must produce interpretable indicators along with the prediction of the risk of fetal hypoxia in order to be appropriated and trusted by practitioners. Finally, common standards should be built and agreed on to evaluate and compare those systems on retrospective cohorts and to validate their use in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Training for breech deliveries with the mother in an upright position: An innovative adaptation of a simulation model.

Author

Farin, Alexandre, Ceccaldi, Pierre-François, Tapie, Laurent, Derisbourg, Sara, Desseauve, David, and Daelemans, Caroline

Subjects
*BREECH delivery, *SIMULATION methods & models, *MOTHERS, *LIKERT scale
Abstract

Background: Delivery of a breech baby with the mother in an upright position or on all fours has gained a renewed interest. In these positions, the obstetrician or midwife needs to learn new landmarks and maneuvers. A realistic simulation model would be a valuable adjunct for breech on all fours teaching programs.Material and Methods: This article describes the simulation model and training program we have developed to train an interprofessional team to assist breech births when the mother is on all fours. A questionnaire was used to evaluate the realism of the adapted mannequin and the impact of training on the confidence level of the participants.Results: On a Likert scale of 1 to 5, 92% of participants agreed or strongly agreed that the adapted mannequin used was realistic for training obstetric maneuvers for complicated breech births. After training, their confidence level supporting a breech birth in an upright position rose from an average of 2.5 to 5.7 on a scale of 1 to 10.Conclusion: Learning the skills for breech deliveries on all fours is made possible by targeted training with this adapted simulation model. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Rilpivirine in HIV-1-positive women initiating pregnancy

Author

Frange, Pierre, Tubiana, Roland, Sibiude, Jeanne, Canestri, Ana, Arvieux, Cédric, Brunet-Cartier, Cécile, Cotte, Laurent, Reynes, Jacques, Mandelbrot, Laurent, Warszawski, Josiane, Le Chenadec, Jérôme, Crenn-Hebert, Catherine, Floch-Tudal, Corinne, Mazy, Fabienne, Joras, Marine, Meier, Françoise, Mortier, Emmanuel, Briquet, Catherine, Ichou, Houria, Marty, Laurence, Jabbarian, Hélène, Ceccaldi, Pierre-François, Villemant, Agnès, Zarouk, Virginie, Lefort, Agnès, Ben Salah, Mariam, Hittinger, Gilles, Chamouilli, Jean-Marc, Burle, Christian, Lafeuillade, Alain, Philip, Gisèle, Lambry, Véronique, Medus, Marie, Bachelard, Germaine, Malet, Martine, Dendale-Nguyen, Joëlle, Guimard, Thomas, Guimard, Karine, Brossier, Jean-Pierre, Perre, Philippe, Esnault, Jean-Luc, Aubry, Olivier, Leautez-Nainville, Sophie, Bonnenfant, Valerie, Laine, Laeticia, Martha, Sandrine-Anne, Maurel, Elise, Francoise, Michel, Barat, Muriel, Murger, Patricia, Rouha, Mahfoud, Lévy, Marc, Lumbroso, Philippe, Checoury, Alain, Sahadatu, Osseni, Perfezou, Pascale, Blondin, Gilles, Ansart, Séverine, De Saint Martin, Luc, Le Moine, Philippe, Duthé, Jean-Charles, Daniel, Corinne, Calvez, Christian, Boutaric, Emmanuelle, Rohan, Jennifer, Bauville, Estelle, Dupre, Christelle, Lotton, Pascal, Ouamara-digue, Enora, Poinsignon, Yves, Goussef, Marie, Grelier, Anne, Mousset, Gaetane, Cudeville, Corinne, Niault, Mathilde, Belzic, Isabelle, Moreau, Philippe, Le Coz, Marie-Françoise, Vaillant, Odile Luycx, Guerin-Duplessy, Anne, Mouton-Rioux, Virginie, De Morel, Philippe, Vitrat, Virginie, Tardif, Didier, Gaillat, Jacques, Vanderbergh, Anne, Braig, Suzanne, Clavere, Gaelle, Dehlinger-Paul, Marion, Mohamed, Khaled, Echard, Marie, Camus, Michel, Mulard, Catherine, Fontelonga, Marie-Agnès, Heller-Roussin, Brigitte, Winter, Cécile, Challier, Marion, Debruyne, Elise, Marcou, Valerie, Firtion, Ghislaine, Pannier, Emmanuelle, Costa, Myriam, Launay, Odile, Salmon-Ceron, Dominique, Belkacem, Touria, Bajawi, Youcef, Aubret, Valérie Raynal, Rivaux, Danièle, Elaoun, Neila, Allal, Lahcene, Djoubou, Sandrine, Rahli, Djamila, Moine, Agnès Bourgeois, Valentin, Morgane, Damond, Florence, Huri, Virginie, Vivier, Valérie, Yahia, Fatma Ait, Garrait, Valérie, Hau, Isabelle, Touboul, Claudine, Ratsimbazafy, Lanto, Boiron, Emilie, Elharrar, Brigitte, Labaune, Jean-Marc, Rudigoz, Rene-Charles, Brochier, Corinne, Galvan, Valérie, Ogoudjobi, Stanislas, Elleau, Christophe, Runel-Belliard, Camille, Pistone, Thierry, Fleury, Hervé, Horovitz, Jacques, Sandler, Boris, Roux, Denis, Ragnaud, Jean-Marie, Chabanier, Pierre, Brun, Jean-Luc, Delveaux, Sandrine, Muanza, Blandine, Diallo, Mama Doufari, Lamaury, Isabelle, Sow, Marie-Thérèse, Samar, Ketty, Carpentier, Bénédicte, Osman, Zafer, Dienga, Etienne, Seaume, Hervé, Ducrocq, Sarah, Bailly-Salin, Philippe, Da Silva, Christelle Dusart, Fayolas, Isabelle, Abbal, Julie, Simon-Toulza, Caroline, Truillet, Véronique, Bogner, Noëlle, Chiabrando, Julie, Armand, Evelyne, Cayla, Claudine, Chacé, Anne, Matheron, Isabelle, Richier, Laurent, Miantezila, Joe, Bry, Sandrine, Couderc, Sophie, Narcy, Catherine, Routier, Corinne, Nassar, Rania, Bouldouyre, Marie-Anne, Zakaria, Ahmed, Dauphin, Hélène, Goissen, Céline, Belloy, Marie, Delassus, Jean-Luc, Favret, Véronique, Nemeth, Céline, Partisani, Marialuisa, Entz-Werlé, Natacha, Langer, Bruno, Uettwiller, Françoise, Durand, Myriam, Partizani, MariaLuisa, Cheneau, Christine, Rey, David, Ebel, Edith, Fischer, Patricia, DAVID, Eric, Vayssière, Christophe, Weil, Michèle, Schmitt, Marie Paule, Nisand, Israël, Genet, Philippe, Brault, Dominique, Allisy, Christine, Gerbe, Juliette, Masse, Virginie, Wifaq, Bouchra, Courdavault, Laurence, Gabor, Petra, Tordjeman, Nathalie, Lebrette, Marie-Gisèle, Selleret, Lise, Samama, Déborah, Bolot, Pascal, Khuong-Josses, Marie-Aude, Amel, Mahdi, Bounan, Stéphane, Nourry, Christelle, Andris, Sabine, Blanche, Stephane, Driessen, Marine, Veber, Florence, Fischer, Alain, Rouzioux, Christine, Avettand-Fenoël, Véronique, Mahlaoui, Nizar, Mourey, Marie-Christine, Granier, Michèle, Devidas, Alain, Donnadieu, Anne-Claire, May, Adrien, Chabrol, Amélie, Chevojon, Pierre, Bellahcene, Chahrazede, Sanchez, Audrey, Malbrunot, Claire, Neizelien, Joelle, Agher, Nouara, Pluchart, Claire, Rouger, Christine, Dommergues, Marc, Bonmarchand, Manuela, Shneider, Luminata, Caby, Fabienne, Calin, Ruxandra-Oana, Blanc, Christine, Lupin, Catherine, Pauchard, Michèle, Yangui, Mohamed Amine, Roca, Didier, Todorova, Darina, Laurent, Juliette, Ferry, A., Deschaud, Martine, Blum, Laurent, Chambrin, Véronique, Labrune, Philippe, Clech, Laure, Raho-Moussa, Mariem, Pauly-Ravelly, Isolde, Jault, Thierry, Bouabdallah, Soufiane, Sanchez, Lydie, Sanchez, Anita, Johnson, Ama, Louchard, Agnès, Allouche, Claude, Pathe, Jean-Paul, Lachassine, Eric, Benoist, Laurence, Jeantils, Vincent, Delannoy, Catherine, Benbara, Amélie, Carbillon, Lionel, Borgne, Anne, Moreau, Laurence, PICARD, Fabienne, Karaoui, Leïla, Elbert, Véronique Lefevre, Balaz, Valérie, Bongain, André, Monpoux, Fabrice, Deville, Anne, Galiba, Eliane, Jabbar, Ahmed, Joutel, Martine, Schmidt, Jean-Luc, Decaux, Nathalie, Cravello, Ludovic, Errichiello, Katia, Hubert, Claire, Dollfus, Catherine, Hervé, François, Tabone, Marie-Dominique, Courcoux, Mary-France, Leverger, Guy, Kayem, Gilles, Schnurgier, Aurélie, Jensen, Aurore, Vaudre, Geneviève, Pinquier, Didier, Gromez, Alexis, Pinto-Cardoso, Gaelle, Faye, Albert, Borie, Constance, Levine, Martine, Matheron, Sophie, Marouts, Erianna Bellaton, Boissinot, Christine, Caseris, Marion, Pommelet, Virginie, Morau, Geneviève, Leveille, Sandrine, Boumediene, Marie Astride, Garion, Dominique, Peretti, Delphine, Fourcade, Corinne, Houllier, Marie, Jrad, Ikram, Bourdic, Katia, Monnier, Sylvie, Chirouze, Catherine, Proust, Aurélie, Catteau, Odile, Gardiennet, Quentin, Reliquet, Véronique, Winer, Norbert, Vaucel, Edouard, Rodallec, Audrey, Garnier-André, Elisabeth, Briandet, Claire, Brouard, Jacques, Goubin, Pascale, Beucher, Gaël, Dina, Julia, Demersay, Arnaud Chalvon, Tassi, Sylvie, Lavarenne, Gaelle, Rajguru, Mandovi, Messaoudi, Fabienne, Carré, Nathalie, Rajguru, Mandavi, Bobrie-Moyrand, Claire, Foucaud, Pierre, Bernard, Louis, Maakroun, Zoha, Bourgault, Olivier, Kebaili, Kamila, Bertrand, Yves, Alixe, Véronique, Boyer, Emeline, Billiemaz, Kareen, Fanget, Cécile, Ronat, Véronique, Lesauder, Catherine, Lavastre, Marie Laure, Moulin, Alice, Turquini, Marie-France, Colombani, Dominique, Belgodere, Danièle, Fialaire, Pascale, Proust, Stéphanie, Rehaiem, Sami, Mesnard, Louis, Werner, Evelyne, Dukiel, Nathalie, Desmergers, Baya, Blanc-Ruffat, Isabelle, Maraux, Barbara, Coursol, Anne, Castaneda, Julie, Etienne, Lise, Vintejoux, Emmanuelle, Lalande, Muriel, Segondy, Michel, Guigue, Nelly, De Gennes, Christiane, Clavel, Cyril, Cazassus, François, Walter, Véronique, Mazingue, Françoise, Hammou, Yamina, Lagree, Marion, Paquiez, Odile, D’angelo, Sophie, Boquet, Laurence, Ajana, Faiza, Hatchuel, Yves, Nahri, Imad, Zebelus, Jenny, Genet, Claire, Ducroix-Roubertou, Sophie, Aubrard, Yves, Constanty, Anne, Weinbreck, Pierre, Piet, Emilie, Jacquier, Françoise, Michaud, Christophe, Safwan, Hassan, Boutet, Arnaud, Grand-Courault, Carole, Autret, Fanny, Habibi, Fakher, Azria, Elie, Abdelhadi, Mohamed, Elenga, Narcisse, Bocket, Laurence, Taillet, Françoise, Palenzuela, Gilles, Khadly, Redouane, Pierronnet, Danielle, Dos-Santos, Emmanuelle, David, Selva, Makhloufi, Djamila, Brunel-Dalmas, Florence, Carbonnel-Delalande, Elisabeth, Chiarello, Pierre, Godinot, Matthieu, Gilbert, Sylvie, Massardier, Jérôme, Gauthier-Moulinier, Hélène, Fernandes, Elisabeth, Ranaivojaona, Sata, Chevry, Coralie, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Maladies infectieuses et tropicales [CHU Tenon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Centre hospitalier universitaire de Nantes (CHU Nantes), Département de maladies infectieuses, Hospices Civils de Lyon (HCL), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Louis Mourier - AP-HP [Colombes], Chirurgie Gynécologique et Obstétrique (CGO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'infectiologie [AP-HP Hôpital Louis Mourier, Colombes], Faculté de Médecine Paris-Diderot [Paris], Université Paris Diderot - Paris 7 (UPD7), Service de Médecine Interne [AP-HP, CHU Beaujon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Beaujon [AP-HP], Service de médecine interne, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer - Hôpital Sainte-Musse, Service de pédiatrie, Centre Hospitalier Chalon-sur-Saône William Morey, CH de Lorient, Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Université de Brest (UBO)-Télécom Bretagne-Institut Mines-Télécom [Paris] (IMT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Unité d'hémato-oncologie, CHU Toulouse [Toulouse], Pôle Médico-Chirurgical de Pédiatrie et de Génétique Clinique, Néonatologie, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Service de Gynécologie et Obstétrique [Rennes] = Gynaecology [Rennes], CH Bretagne Sud, Centre d'Investigations Biomédicales - Hématologie - Oncologie - Greffes (CIB-HOG), Centre d'Investigations Biomédicales - Hématologie - Oncologie - Greffes-Hopital St Louis, Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Service des Maladies Infectieuses, Centre Hospitalier de la Région d'Annecy (Pringy), University of Warwick [Coventry], Physiopathologie et Pharmacotoxicologie Placentaire Humaine (U1139), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Service de Virologie [CHU Bichat], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Hôpital de la Croix-Rousse [CHU - HCL], Réseau périnatal Aurore, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Bordeaux [Bordeaux], pôle gynécologie-obstétrique et médecine foetale, Laboratoire Rhéologie et Procédés (LRP), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Fédération des Maladies Infectieuses [Bordeaux], CHU de Bordeaux Pellegrin [Bordeaux], Centre de compétences des microangiopathies thrombotiques, department of pathology, university hospital, parakou, CHU Pointe-à-Pitre/Abymes [Guadeloupe], Service des Maladies Infectieuses et Tropicales[Point-à-Pitre], Service de Gynécologie-Obstétrique [Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), CHU Strasbourg, Développement et physiopathologie de l'intestin et du pancréas, Institut National de la Santé et de la Recherche Médicale (INSERM), Service de gynécologie–obstétrique, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], CHRU Strasbourg, Département d'échographie et de Médecine fœtale, SIHCUS-CMCO, Service de Gynécologie-Obstétrique, CHI Poissy-Saint-Germain, Centre Hospitalier Victor Dupouy, Service d'informatique médicale et biostatistiques [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Hôpital d'Argenteuil, Centre Hospitalier de Saint-Denis [Ile-de-France], Hôpital Delafontaine, Recherche Epidémiologique en Santé Périnatale et Santé des Femmes et des Enfants (UMR_S 953), Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de microbilogie & unité d'immunologie, hématologie et rhumatologie pédiatriques, Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), Laboratoire de Virologie [CHU Necker], Université Sorbonne Paris Cité (USPC), IFR Necker-Enfants Malades (IRNEM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Médecine néonatale, Centre Hospitalier Sud Francilien, Service de pneumologie [Béclère], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Gynécologie-Obstétrique, Maternité, Chirurgie Gynécologique [CHU Pitié-Salpêtrière], Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Croissance cellulaire, réparation et régénération tissulaires (CRRET), Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), Hôpital Antoine Béclère, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Référence Maladies Héréditaires du Métabolisme Hépatique [Hôpital Antoine Béclère - APHP (CRMR), Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Service de gynécologie-obstétrique [Hôpital Jean Verdier], Université Paris 13 (UP13)-Hôpital Jean Verdier [AP-HP], Service de Gynécologie-Obstétrique-Reproduction, Hôpital l'Archet, Service d'Hémato-oncologie Pédiatrique [CHU Nice], Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU Trousseau [APHP], Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables (ECEVE (U1123 / UMR_S_1123)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Service des maladies infectieuses et tropicales, Service de pédiatrie générale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Institut Pasteur du Laos, Réseau International des Instituts Pasteur (RIIP), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service de Gynécologie Obstétrique, Service de Médecine Interne et Immunologie clinique [AP-HP Hôpital Bicêtre], Hôpital Bicêtre, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), service de maladies infectieuses CHU J Minjoz Besancon, Service des maladies infectieuses et tropicales [CHU Nantes], Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de virologie [CHU Nantes], Service de Pédiatrie Enfants - Hématologie Oncologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de Pédiatrie Médicale [Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Gynécologie-Obstétrique et Médecine de la Reproduction [CHU Caen], Service de Virologie [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Médecine Interne et Maladies Infectieuses [Tours], Service d'hématologie : Immuno-Hématologie pédiatrique et transplantation de moelle osseuse, Hôpital Debrousse, CHU Saint-Etienne, Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5), Médecine Néonatale et Réanimation Pédiatrique, CH René Dubos, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service des Maladies Infectieuses et Tropicales [Hôpital Gustave Dron, Tourcoing], Centre Hospitalier Gustave Dron [Tourcoing], 'Personal Protection Against Vectors' working group (PPAV), PPAV working group, Service des Maladies infectieuses et tropicales [CHU Limoges], CHU Limoges, Equipe de Recherche Médicale Appliquée (ERMA), Université de Limoges (UNILIM)-CHU Limoges-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), CHU Annecy, Service de Pédiatrie, Centre hospitalier de Saint-Nazaire, EA 3593 Université des Antilles et de la Guyane, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Laboratoire de virologie [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Service d'immunologie, Hospices Civils de Lyon (HCL)-Hôpital Edouard Herriot [CHU - HCL], Hôpital Femme Mère Enfant [CHU - HCL] (HFME), Centre Hospitalier de Basse-Terre, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Université de Rennes (UR), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Collège de France - Chaire Médecine expérimentale (A. Fischer), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), ANRS CO1/CO11, French national, Viral Hepatitis, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Service des maladies infectieuses et tropicales [CHU Tenon], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), Hôpital des Enfants, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris-Sud - Paris 11 (UP11), CH Evry-Corbeil-CH Evry-Corbeil, CH Evry-Corbeil, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13), Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Laboratoire d'Electrotechnique de Lyon (LEL), École Centrale de Lyon (ECL), Université de Lyon-Université de Lyon, Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Université de Limoges (UNILIM)-CHU Limoges, Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital universitaire Robert-Debré [Paris], Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM)

Subjects
rilpivirine, viral suppression, hiv, hiv-1, pregnancy, conception, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, virology
Abstract

International audience; BackgroundSafety data about rilpivirine use during pregnancy remain scarce, and rilpivirine plasma concentrations are reduced during second/third trimesters, with a potential risk of viral breakthroughs. Thus, French guidelines recommend switching to rilpivirine-free combinations (RFCs) during pregnancy.ObjectivesTo describe the characteristics of women initiating pregnancy while on rilpivirine and to compare the outcomes for virologically suppressed subjects continuing rilpivirine until delivery versus switching to an RFC.MethodsIn the ANRS-EPF French Perinatal cohort, we included women on rilpivirine at conception in 2010–18. Pregnancy outcomes were compared between patients continuing versus interrupting rilpivirine. In women with documented viral suppression (

Published
2020

31. Alternative to Intensive Management of the Active Phase of the Second Stage of Labor: A Multicenter Randomized Trial (Phase Active du Second STade Trial) Among Nulliparous Women With an Epidural.

Author

Le Ray, Camille, Rozenberg, Patrick, Kayem, Gilles, Harvey, Thierry, Sibiude, Jeanne, Doret, Muriel, Parant, Olivier, Fuchs, Florent, Vardon, Delphine, Azria, Elie, Sénat, Marie-Victoire, Ceccaldi, Pierre-François, Seco, Aurélien, Garabedian, Charles, and Chantry, Anne Alice

Published
2023
Full Text
View/download PDF

35. Nutrition parentérale et grossesse.

Author

Billiauws, Lore, Ceccaldi, Pierre-François, and Joly, Francisca

Subjects
*SHORT bowel syndrome, *RARE diseases, *PARENTERAL feeding, *QUALITY of life, *BOWEL obstructions
Abstract

L'insuffisance intestinale chronique (IIC) est une situation clinique rare dont la principale cause est le syndrome de grêle court (SGC). La pseudo-obstruction intestinale chronique (POIC) est également une cause d'IIC. La nutrition parentérale à domicile (NPAD) a permis d'augmenter la survie et la qualité de vie des patients ayant une insuffisance intestinale chronique. Plusieurs grossesses sous NPAD ont été décrites. L'objectif de cette revue est de faire la synthèse sur l'état des connaissances sur les grossesses en NPAD, et de faire le point sur les adaptations nécessaires des traitements et de la nutrition. En NPAD prolongée, les grossesses sont donc possibles, mais le taux de complications maternelles liées à la maladie sous-jacente et à la NP est élevé. Un suivi rapproché et une préparation à la grossesse doivent être réalisés afin de prévenir et traiter d'éventuelles carences et leurs effets délétères. Chronic intestinal failure is a rare disease and short bowel syndrome is its main etiology. Chronic intestinal pseudo obstruction (CIPO) is also a cause of IIC. Home parenteral nutrition (HPN) has improved survival and quality of life of patients with IIC. Some pregnancy during HPN have been reported. The aim of this review was to summarize the state of knowledge on pregnancy during HPN, and to resume the needed adaptations of treatments and PN. During long term HPN, pregnancy are possible but the complication rate, due to PN and to underlying disease, is high. A close follow-up end pregnancy preparation are necessary, in order to prevent and treat some deficiencies and their deleterious effects. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

36. Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model

Author

Mandelbrot, Laurent, Ceccaldi, Pierre-François, Duro, Dominique, Lê, Minh, Pencolé, Lucile, Peytavin, Gilles, Service de Gynécologie-Obstétrique [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Diderot - Paris 7 (UPD7), DHU Risques Et Grossesse, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Service de Gynécologie-Obstétrique [Clichy], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), Service de Pharmaco-Toxicologie [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], The salary of Dominique Duro was funded by the Agence Nationale de Recherches sur le Sida et Hépatites Virales (Inserm-ANRS). The Agence Nationale de Recherches sur le Sida et Hépatites Virales (Inserm-ANRS) also also provided funding to purchase equipment and for publication costs., Bodescot, Myriam, Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Beaujon [AP-HP]

Subjects
RNA viruses, Embryology, Placenta, Maternal Health, Pathology and Laboratory Medicine, Biochemistry, Piperazines, Immunodeficiency Viruses, Drug Metabolism, Pregnancy, Medicine and Health Sciences, Public and Occupational Health, Maternal-Fetal Exchange, Obstetrics and Gynecology, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Vaccination and Immunization, [SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences, Perfusion, Medical Microbiology, Viral Pathogens, Viruses, Medicine, Female, Anatomy, Pathogens, Heterocyclic Compounds, 3-Ring, Research Article, Pyridones, Science, Immunology, Antiretroviral Therapy, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, Microbiology, Models, Biological, Antiviral Therapy, Albumins, Retroviruses, Oxazines, Placental Cotyledon, Humans, Pharmacokinetics, HIV Integrase Inhibitors, Microbial Pathogens, Pharmacology, Lentivirus, Reproductive System, Organisms, Biology and Life Sciences, Proteins, HIV, [SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, Women's Health, Preventive Medicine, Antipyrine, Developmental Biology
Abstract

ObjectiveTo determine the transplacental pharmacokinetics of the HIV integrase inhibitor dolutegravir.Study designMaternal-to-fetal transfer across the term human placenta was investigated with the ex-vivo dually perfused cotyledon model, in 5 closed-circuit, recirculating experiments. Dolutegravir was added to a maternal perfusate containing antipyrine, a marker to validate the cotyledon's viability, and 2 g/liter of human albumin.ResultsAfter 3h of recirculating perfusion, the mean (± SD) DTG concentrations in the maternal and in the fetal compartments were respectively 2450 ± 286 ng/mL and 715 ± 369 ng/mL, with a fetal-to-maternal ratio of 34% ± 18% and a clearance index (in comparison with antipyrine transfer) of 79% ± 23%. The mean cotyledon accumulation index was 153% ± 25%.ConclusionFetal transplacental exposure to dolutegravir was considerable as well as accumulation in placental tissue. Whether this may lead to risks for the exposed fetus requires more investigation.

Published
2019

39. Advanced Interventional Procedures after Intrauterine Tamponade Balloon Insertion in a Tertiary Care Center.

Author

Habib, Nassir, Luton, Dominique, Centini, Gabriele, Renuit, Isabelle, Birbarah, Christian, and Ceccaldi, Pierre-François

Subjects
TERTIARY care, ERYTHROCYTES, THERAPEUTIC embolization, CESAREAN section, TRACHELECTOMY, LABOR (Obstetrics), PROTHROMBIN time
Abstract

To evaluate the rate of success and practicability of the intrauterine tamponade balloon (ITB) for managing PPH as a fertility-sparing tool. Methods: a five-year retrospective monocentric study in a tertiary care center including patients transferred for severe PPH. Results: In 231 patients, the success rate of ITB (n = 57), embolization (n = 58), and medical management (n = 114) was 84.21%, 74.13%, and 76.32%, respectively. Cesarean section during labor did not influence the risk of advanced interventional procedures (AIPs) for patients with ITB (odds ratio [OR] = 1.08) but did so in patients who were under expectant management in the intensive care (OR = 5.29). In the AIP subgroup of the ITB group, hemostasis was significantly deteriorated. Prothrombin time <50% (OR = 11.5), fibrinogen <2 g/L (OR = 6.88), and >4 red blood cells units (RBCs) transfused (OR = 17.2) were associated with a significantly higher risk of failure. Blood loss in the AIP patients in the embolization group was significantly higher. Patients requiring >4 units of RBCs were 22.9 times more likely to have an AIP (p =.0001). Conclusion: Compared with uterine embolization and medical management, ITB use in a tertiary care center was associated with lower risk of undergoing AIP, but further prospective study is required to confirm this. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

40. Management of patients with rare blood groups in maternity.

Author

Pytel, Shannon, Ceccaldi, Pierre-François, Idri, Salim, Ohayon, Jordan, and Badoiu, Diana

Subjects
*BLOOD grouping & crossmatching, *BLOOD transfusion, *PREGNANT women, *ANEMIA treatment, *HYDROPS fetalis, *PURE red cell aplasia
Abstract

We report on our experiences since 2010 with pregnant women with rare blood types. The lack of compatible blood is a challenge for the anaesthetist whose priority is to prevent and treat anaemia in late pregnancy in order to avoid immunisation after transfusion of incompatible blood. In our hospital, the blood type is checked during the first obstetric consult, which is variable, starting from the fourth month of pregnancy. Rare blood types are most often diagnosed in an advanced stage of pregnancy (30 weeks of gestation: WG) due to the late inscription for obstetrics consult, resulting in even later anaesthetic visit. In our 13 patients, the most common blood systems are Duffy, MNS, and RH. 61.5% of the patients have associated antibodies (anti-MNS5). The majority of patients received iron with significant increase of ferritin (17.24 ± 12.95 μg/L versus 262.2 ± 404.4 μg/L, p =.033). Six of the patients had 2–3 injections of EPO between 29 – 36 + 1 WG. There were no transfers for paediatric management of haemolytic disease in the newborn following the birth. Overall, this treatment of patients with a rare blood group has also changed our practices for the follow-up of other pregnant women, and ferritin is more regularly prescribed. What is already known on this subject? For rare blood groups, the frequency in the general population is less than 1/4000. The most common antibodies at risk of haemolytic disease and 'hydrops fetalis' are anti-D, anti-E, anti-C, and anti-K. The survey of pregnant women with a rare blood type takes into account the maternal risk of 'transfusion deadlock' and haemolytic disease of the newborn. What do the results of this study add? Rare blood types are most often diagnosed in an advanced stage of pregnancy (30 WG) due to the late inscription for obstetrics consults at Maternity. The most common blood systems are Duffy, MNS, RH, and 61.5% of the patients have associated antibodies (anti-MNS5). The most efficient treatment of prenatal anaemia was iron perfusions who allowed significant increase of ferritin and a maternal haemoglobin concentration of 12.1±1.46 g/dL in the ninth month of pregnancy. What are the implications of these findings for clinical practice and/or further research? A pregnant woman with a rare blood group is a situation that requires a technical platform specialised in haemorrhagic risk and a multidisciplinary team, including a blood bank as well as anaesthetic and obstetrical teams, with excellent interdisciplinary coordination. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

42. Management of patients with rare blood groups in maternity.

Author

Pytel, Shannon, Ceccaldi, Pierre-François, Idri, Salim, Ohayon, Jordan, and Badoiu, Diana

Abstract

We report on our experiences since 2010 with pregnant women with rare blood types. The lack of compatible blood is a challenge for the anaesthetist whose priority is to prevent and treat anaemia in late pregnancy in order to avoid immunisation after transfusion of incompatible blood. In our hospital, the blood type is checked during the first obstetric consult, which is variable, starting from the fourth month of pregnancy. Rare blood types are most often diagnosed in an advanced stage of pregnancy (30 weeks of gestation: WG) due to the late inscription for obstetrics consult, resulting in even later anaesthetic visit. In our 13 patients, the most common blood systems are Duffy, MNS, and RH. 61.5% of the patients have associated antibodies (anti-MNS5). The majority of patients received iron with significant increase of ferritin (17.24 ± 12.95 μg/L versus 262.2 ± 404.4 μg/L, p = .033). Six of the patients had 2-3 injections of EPO between 29 - 36 + 1 WG. There were no transfers for paediatric management of haemolytic disease in the newborn following the birth. Overall, this treatment of patients with a rare blood group has also changed our practices for the follow-up of other pregnant women, and ferritin is more regularly prescribed.Impact statementWhat is already known on this subject? For rare blood groups, the frequency in the general population is less than 1/4000. The most common antibodies at risk of haemolytic disease and 'hydrops fetalis' are anti-D, anti-E, anti-C, and anti-K. The survey of pregnant women with a rare blood type takes into account the maternal risk of 'transfusion deadlock' and haemolytic disease of the newborn.What do the results of this study add? Rare blood types are most often diagnosed in an advanced stage of pregnancy (30 WG) due to the late inscription for obstetrics consults at Maternity. The most common blood systems are Duffy, MNS, RH, and 61.5% of the patients have associated antibodies (anti-MNS5). The most efficient treatment of prenatal anaemia was iron perfusions who allowed significant increase of ferritin and a maternal haemoglobin concentration of 12.1±1.46 g/dL in the ninth month of pregnancy.What are the implications of these findings for clinical practice and/or further research? A pregnant woman with a rare blood group is a situation that requires a technical platform specialised in haemorrhagic risk and a multidisciplinary team, including a blood bank as well as anaesthetic and obstetrical teams, with excellent interdisciplinary coordination. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

43. Simulation and professional development: added value of 3D modelization in reproductive endocrinology and infertility and assisted reproductive technologies teamwork.

Author

Ceccaldi, Pierre-François, Pirtea, Paul, Lemarteleur, Vincent, Poulain, Marine, Ziegler, Dominique De, and Ayoubi, Jean-Marc

Subjects
*ENDOCRINOLOGY of human reproduction, *REPRODUCTIVE technology, *CAREER development, *INFERTILITY, *DIGITAL printing
Abstract

As in other specialties of medicine, there is more to clinical performance in reproductive endocrinology, infertility, and assisted reproductive technologies (REI-ART) than simply the individual knowledge and technical skills. Simulation is commonly used during fellowship training in REI-ART, aiming to produce a virtual cycle of professional development in order to improve patient outcome. With scientific certification and the joint development of evaluation tools, the contribution of digitalization, such as 3 D printing and digital simulators, will facilitate teamwork in REI-ART and enable a better transmission of knowledge in the specialty. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

45. 3D-printed protected face shields for health care workers in Covid-19 pandemic.

Author

Lemarteleur, Vincent, Fouquet, Vincent, Le Goff, Stéphane, Tapie, Laurent, Morenton, Pascal, Benoit, Aurélie, Vennat, Elsa, Zamansky, Bruno, Guilbert, Thomas, Depil-Duval, Arnaud, Gaultier, Anne-Laure, Tavitian, Bertrand, Plaisance, Patrick, Tharaux, Pierre-Louis, Ceccaldi, Pierre-François, Attal, Jean-Pierre, and Dursun, Elisabeth

Abstract

• Eye-protecting devices are crucial to cut off virus transmission via conjunctiva. • 3D-printing devices inside hospital setting allows rapid and large-scale manufacture. • An ongoing dialogue in an interdisciplinary group allows iterative improvements. The coronavirus pandemic resulted in a shortage of protective equipment. To meet the request of eye-protecting devices, an interdisciplinary consortium involving practitioners, researchers, engineers and technicians developed and manufactured thousands of inexpensive 3D-printed face shields, inside hospital setting. This action leads to the concept of "concurrent, agile, and rapid engineering". [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

47. Foetal Thyroid Dysfunction: Treat the Mother First!

Author

Khater, Carine, Ceccaldi, Pierre François, Poujade, Olivier, Banigé, Maïa, Ottenwalter, Annick, and Luton, Dominique

Subjects
*THYROID diseases, *GOITER, *HYPERTHYROIDISM, *FETAL diseases, *CONGENITAL disorders
Abstract

A case is presented of foetal compensated hypothyroidism due to persisting low maternal serum FT4 at the beginning of pregnancy. Diagnosis was made by means of foetal ultrasound followed by foetal blood sampling because of atypical findings. Foetal thyroid hypertrophy resolved progressively as exogenous thyroxine was administered to the mother. This case highlights once again the importance of adequate thyroid function during pregnancy. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

48. Anti-TPO Antibodies Diffusion through the Placental Barrier during Pregnancy.

Author

Seror, Jérémy, Amand, Gaëlle, Guibourdenche, Jean, Ceccaldi, Pierre-François, and Luton, Dominique

Subjects
IODIDE peroxidase, AUTOIMMUNE thyroiditis, HYPOTHYROIDISM, ETIOLOGY of diseases, ENZYME inhibitors, PLACENTA, PREGNANCY
Abstract

Background: Hashimoto’s thyroiditis is the principal aetiology of hypothyroidism with presence of anti-thyroperoxidase antibodies (anti-TPO). The association between anti-TPO and foeto-placental complications has been observed in previous studies. To go further in the understanding, the current study compares the level of anti-TPO in maternal blood and in the cord blood of her fetus at the moment of childbirth to demonstrate the passage of anti-TPO through the placenta barrier. Methods and Findings: This study was realised in a maternity ward located in the Northern district of Paris, France from 2006 to 2007. Women with normal pregnancy were included in a first study and only women with no abnormal thyroid dosage at baseline and tested positive with anti-TPO were prospectively enrolled. Maternal blood samples were collected in the third trimester and at the arrival to the ward when patients came to deliver. After delivery, cord blood sample was collected. Pearson’s correlation coefficient was computed. 5941 patients delivered in the ward during the study, 33 pregnant women were included. We found a correlation between the anti-TPO levels in maternal and in the cord blood of their fetus with a correlation coefficient of 0.98 and a p-value<0.001. Conclusions: This is the first demonstration of the free passage through the placental barrier of anti-TPO from the mother to the fetus at the moment of childbirth. These findings can be extrapolated all along pregnancy and open the door to a direct action of the anti-TPO on fetus and to a possible action on the fetal thyroid. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

49. Uterine necrosis following pelvic arterial embolization for post-partum hemorrhage: review of the literature.

Author

Poujade, Olivier, Ceccaldi, Pierre François, Davitian, Carine, Amate, Pascale, Chatel, Paul, Khater, Carine, Aflak, Nizar, Vilgrain, Valérie, and Luton, Dominique

Subjects
*UTERINE fibroids, *PELVIC diseases, *ARTERIAL diseases, *THERAPEUTIC embolization, *CESAREAN section, *COMPUTED tomography
Abstract

Abstract: Uterine necrosis is one of the rarest complications following pelvic arterial embolization for postpartum hemorrhage (PPH). With the increasing incidence of cesarean section and abnormal placental localization (placenta previa) or placental invasion (placenta accreta/increta/percreta), more and more cases of uterine necrosis after embolization are being diagnosed and reported. Pelvic computed tomography or magnetic resonance imaging provides high diagnostic accuracy, and surgical management includes hysterectomy. We performed a Medline database query following the first description of uterine necrosis after pelvic embolization (between January 1985 and January 2013). Medical subheading search words were the following: “uterine necrosis”; “embolization”; “postpartum hemorrhage”. Seventeen citations reporting at least one case of uterine necrosis after pelvic embolization for PPH were included, with a total of 19 cases. This literature review discusses the etiopathogenesis, clinical and therapeutic aspects of uterine necrosis following pelvic arterial embolization, and guidelines are detailed. The mean time interval between pelvic embolization and diagnosis of uterine necrosis was 21 days (range 9–730). The main symptoms of uterine necrosis were fever, abdominal pain, menorrhagia and leukorrhea. Surgical management included total hysterectomy (n =15, 78%) or subtotal hysterectomy (n =2, 10%) and partial cystectomy with excision of the necrotic portion in three cases of associated bladder necrosis (15%). Uterine necrosis was partial in four cases (21%). Regarding the pathophysiology, four factors may be involved in uterine necrosis: the size and nature of the embolizing agent, the presence of the anastomotic vascular system and the embolization technique itself with the use of free flow embolization. [Copyright &y& Elsevier]

Published
2013
Full Text
View/download PDF

50. Modulation of Free Corticotrophin-Releasing Hormone, Adrenal and Placental Steroid Hormone Levels Induced by Mifepristone during Pregnancy.

Author

Ceccaldi, Pierre-François, Saada, Julien, Nicolas, Mireille, Ducarme, Guillaume, Blot, Philippe, Guibourdenche, Jean, and Luton, Dominique

Subjects
*PEPTIDE hormones, *ADRENOCORTICAL hormones, *STEROID hormones, *MIFEPRISTONE, *PREGNANCY, *PROGESTERONE receptors
Abstract

Mifepristone is a progesterone receptor antagonist widely used in obstetrics. The aim of the study was to focus on free corticotrophin-releasing hormone (CRH) and also describe modulation of adrenal and placental steroid hormone concentrations induced by mifepristone. Methods: Twenty-six women were enrolled in the study. They received mifepris-tone for termination of pregnancy. Maternal blood samples were retrieved before administration of mifepristone (600 mg) and 48 h after, just before induction of labor. Bound and free CRH levels were determined in maternal blood concomitantly with Cortisol, estriol, progesterone and SDHEA levels. Also paired fetal cord blood samples were collected. Results: Maternal plasmatic CRH level did not change after mifepristone absorption but free CRH increased significantly (0.500 ± 0.326 vs. 0.388 ± 0.303 ng/ml, p = 0.040). A significant decrease of progesterone was observed (83.6 ± 49.3 vs. 95.6 ± 54.9 ng/ml, p = 0.001) with a lower progester-one/estriol ratio (26.9 ± 15.7 vs. 40.7 ± 31.1, p = 0.004). There was a strong association between maternal and fetal free CRH (r² = 0.675, p = 0.001), Cortisol (r² = 0.570, p = 0.019), and positive but modest correlation for progesterone (r² = 0.341, p = 0.046) and estriol (r² = 0.379, p = 0.025) levels. Conclusion: Mifepristone has an effect on free CRH level and changes the estriol-progesterone balance. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results